“…There are specific advantages of using a eukaryotic system over the E. coli commercial kits available, including the ability to perform post‐translational modifications, such as disulfide bond formation. The system outlined below is capable of producing 116.2 µg/ml of human serum albumin (HSA; Spice, Aw, Bracewell, & Polizzi, 2020a), a complex biopharmaceutical containing numerous disulfide bonds. These yields exceed the reported GFP production in HeLa (Mikami, Masutani, Sonenberg, Yokoyama, & Imataka, 2006) and RRL systems (Kobs, 2008), and luciferase in CHO Brodel et al., 2014), insect (Ezure et al., 2006) and S. cerevisiae platforms (Gan & Jewett, 2014).…”